GET DAILY SIGNALSThe Cigna Group (CI) Delivers Q3 Earnings Beat and Raises Full-Year Outlook
Key Takeaways
- The Cigna Group reported third quarter 2026 adjusted earnings per share (EPS) of $7.98, exceeding Wall Street's consensus estimate of roughly $7.50.
- Total revenue rose 6% year over year to $73.7 billion, slightly above analyst expectations of about $72.7 billion.
- GAAP net income declined to $1.4 billion, or $5.47 per share, largely reflecting the absence of a prior-year gain on a business sale.
- Management raised its full-year 2026 adjusted EPS outlook to at least $30.60, up from a prior projection of at least $30.45.
- The Cigna Healthcare medical care ratio (MCR) was 85.0%, compared with 84.8% a year earlier.
- Executives flagged several 2027 headwinds, including shrinking industry rebate pools and a planned exit from the ACA exchange business.
Why These Results Matter
The Cigna Group's quarterly results offer investors insight into both health insurance fundamentals and the broader pharmacy services market. The company operates through two primary segments: Evernorth Health Services, which includes pharmacy benefit and specialty services, and Cigna Healthcare, which provides employer-sponsored and other medical coverage. With Evernorth generating the majority of consolidated revenue, Cigna (CI) has become more services-weighted than many of its insurance peers. This report matters because it reveals how premium rate increases, medical cost trends, and specialty pharmacy demand are translating into profitability, while also setting the stage for management's 2027 outlook and its ongoing "Accelerate to One" cost-efficiency initiative. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Quarterly Results in Detail
For the third quarter ended September 30, 2026, The Cigna Group reported total revenues of $73.7 billion, a 6% increase from $69.7 billion in the prior-year period. Adjusted income from operations was $2.1 billion, or $7.98 per share, up modestly from $7.83 per share a year ago and above the consensus estimate of approximately $7.50.
Shareholders' net income under GAAP was $1.4 billion, or $5.47 per share, down from $1.9 billion, or $6.98 per share, in the third quarter of 2025. The decline primarily reflected the absence of an after-tax gain on a business sale recognized in the prior-year period, along with amortization of acquired intangible assets and certain special items.
By segment, Evernorth adjusted revenues increased about 6% to $63.8 billion, while Cigna Healthcare adjusted revenues rose approximately 9% to $11.7 billion, driven by premium rate increases. The Cigna Healthcare MCR of 85.0% was up 20 basis points year over year, largely due to U.S. Employer business mix. Management raised full-year 2026 adjusted EPS guidance to at least $30.60 and narrowed the expected 2026 MCR range to 84.2%, plus or minus 25 basis points.
Market Reaction and Outlook Considerations
Shares of The Cigna Group moved modestly higher in the hours after the report, with the stock initially trading up roughly 2% in pre-market activity before settling near $304 to $311 during the session, according to market data. The upbeat reaction reflected the adjusted EPS beat and the raised full-year outlook, which reinforced confidence in management's execution.
At the same time, the market appeared to weigh the company's 2027 commentary carefully. Executives reiterated expectations for at least 10% adjusted EPS growth in 2027 but highlighted several headwinds, including smaller industry rebate pools, lower employer coverage of GLP-1 weight-loss drugs, fewer biosimilar and specialty generic launches, and the planned exit from the ACA exchange business. This mix of near-term strength and forward-looking caution kept the stock's response measured.
Key Factors to Watch Going Forward
Looking ahead, investors will be watching how The Cigna Group balances its 2026 momentum against the headwinds management has already identified for 2027. The company's fourth quarter call is expected to provide comprehensive 2027 guidance, which will be a key catalyst for the stock.
One area to monitor is the medical care ratio. While the 2026 MCR outlook was narrowed to 84.2%, plus or minus 25 basis points, any sustained increase in medical cost trends could pressure margins in the Cigna Healthcare segment.
Within Evernorth, the trajectory of specialty pharmacy, biosimilar adoption, and pharmacy benefit services revenue will remain in focus. Management has pointed to a strong 2027 selling season with high client retention, but shrinking rebate pools and lower GLP-1 coverage could temper growth.
Finally, the "Accelerate to One" modernization and productivity initiative, a multi-year, $3 billion program, will be worth tracking as cost savings begin to flow through results. Together, these factors will shape whether the company can sustain its long-term targets of 10% to 14% adjusted EPS growth and approximately $50 billion in cumulative operating cash flow through 2030.
My Approach to Earnings Analysis
When reviewing results like these, I find it helpful to cross-reference with data-driven tools that highlight patterns across the sector. Tickeron’s AI Screener has become a regular part of that process for me, allowing quick scans for comparable names and technical setups that might influence how I view the broader opportunity set.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CI's RSI Indicator recovers from overbought zone
The 10-day RSI Oscillator for CI moved out of overbought territory on October 23, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 37 instances where the indicator moved out of the overbought zone. In 25 of the 37 cases the stock moved lower in the days that followed. This puts the odds of a move down at 68%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for CI turned negative on October 29, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 27 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 53%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
CI broke above its upper Bollinger Band on October 14, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on CI as a result. In 65 of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 70%.
CI moved above its 50-day moving average on October 07, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for CI crossed bullishly above the 50-day moving average on October 14, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 62%.
The 50-day moving average for CI moved above the 200-day moving average on October 16, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +3.46% 3-day Advance, the price is estimated to grow further. Considering data from situations where CI advanced for three days, in 220 of 352 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.
The Aroon Indicator entered an Uptrend today. In 176 of 276 cases where CI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 64%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 19 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.894) is normal, around the industry mean (3.512). P/E Ratio (12.563) is within average values for comparable stocks, (126.100). Projected Growth (PEG Ratio) (0.739) is also within normal values, averaging (0.786). CI has a moderately high Dividend Yield (0.020) as compared to the industry average of (0.009). P/S Ratio (0.264) is also within normal values, averaging (0.569).
The Tickeron Price Growth Rating for this company is 28 (best 1 - 100 worst), indicating outstanding price growth. CI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 40 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 43 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock slightly better than average.
The Tickeron SMR rating for this company is 55 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of health insurance services
Industry ManagedHealthCare
Advertisement